MetLife Investment Management LLC Reduces Stock Position in Encompass Health Co. (NYSE:EHC)

MetLife Investment Management LLC lessened its holdings in shares of Encompass Health Co. (NYSE:EHC) by 1.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 51,978 shares of the company’s stock after selling 1,010 shares during the period. MetLife Investment Management LLC’s holdings in Encompass Health were worth $5,023,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Magnetar Financial LLC boosted its stake in shares of Encompass Health by 1,176.6% during the 2nd quarter. Magnetar Financial LLC now owns 744,836 shares of the company’s stock valued at $63,899,000 after purchasing an additional 814,018 shares in the last quarter. Thrivent Financial for Lutherans lifted its holdings in Encompass Health by 2,302.7% in the second quarter. Thrivent Financial for Lutherans now owns 603,558 shares of the company’s stock worth $51,780,000 after buying an additional 578,438 shares during the period. AQR Capital Management LLC boosted its position in Encompass Health by 213.3% during the 2nd quarter. AQR Capital Management LLC now owns 207,202 shares of the company’s stock valued at $17,776,000 after acquiring an additional 141,075 shares in the last quarter. Cubist Systematic Strategies LLC grew its holdings in shares of Encompass Health by 762.4% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 83,347 shares of the company’s stock worth $7,150,000 after acquiring an additional 73,683 shares during the period. Finally, Algert Global LLC raised its position in shares of Encompass Health by 89.5% in the 3rd quarter. Algert Global LLC now owns 150,570 shares of the company’s stock worth $14,551,000 after acquiring an additional 71,132 shares in the last quarter. Institutional investors own 97.25% of the company’s stock.

Encompass Health Price Performance

Shares of EHC opened at $102.94 on Monday. The company has a market capitalization of $10.37 billion, a P/E ratio of 24.86, a price-to-earnings-growth ratio of 1.36 and a beta of 0.88. Encompass Health Co. has a twelve month low of $63.78 and a twelve month high of $104.55. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.88. The firm has a 50 day moving average of $98.16 and a 200 day moving average of $91.42.

Encompass Health (NYSE:EHC) last posted its quarterly earnings results on Monday, October 28th. The company reported $1.03 earnings per share for the quarter, topping the consensus estimate of $0.94 by $0.09. Encompass Health had a return on equity of 17.60% and a net margin of 8.10%. The firm had revenue of $1.35 billion during the quarter, compared to analysts’ expectations of $1.33 billion. During the same quarter in the previous year, the business earned $0.86 earnings per share. The company’s revenue was up 11.9% on a year-over-year basis. As a group, equities research analysts anticipate that Encompass Health Co. will post 4.29 earnings per share for the current fiscal year.

Encompass Health Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, January 15th. Stockholders of record on Thursday, January 2nd will be paid a $0.17 dividend. The ex-dividend date is Thursday, January 2nd. This represents a $0.68 dividend on an annualized basis and a dividend yield of 0.66%. Encompass Health’s dividend payout ratio is presently 16.43%.

Wall Street Analyst Weigh In

Several brokerages recently weighed in on EHC. Truist Financial reaffirmed a “buy” rating and issued a $116.00 price target (up from $108.00) on shares of Encompass Health in a research note on Wednesday, October 30th. UBS Group increased their price target on shares of Encompass Health from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Wednesday, September 25th. Royal Bank of Canada boosted their price objective on shares of Encompass Health from $105.00 to $110.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. Barclays raised their target price on shares of Encompass Health from $109.00 to $116.00 and gave the company an “overweight” rating in a research note on Tuesday, October 29th. Finally, Stephens reiterated an “overweight” rating and set a $105.00 target price on shares of Encompass Health in a report on Tuesday, August 6th. Nine investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Encompass Health has an average rating of “Buy” and an average price target of $107.11.

Encompass Health Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.